Efficacy of Duohuojisheng decoction monotherapy for the treatment of knee osteoarthritis

A protocol of a systematic review of randomized controlled trials

Zhi-ling Hou, MMa, Bo-yang Yuan, MMb, Ming-xia Fu, MBb, Lei Ni, MMc, Qiang Bao, MBd

Abstract
Background: This systematic review investigates the efficacy and safety of Duohuojisheng decoction (DHJSD) monotherapy for the treatment of patients with knee osteoarthritis (KOA).

Methods: We searched relevant studies on DHJSD monotherapy for KOA from the databases of CENTRAL, EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data from the inception to January 1, 2019. Two researchers independently selected studies, collected data, and assessed the methodology quality by using Cochrane risk of bias tool.

Results: This study evaluates the efficacy and safety of DHJSD monotherapy for KOA by assessing the pain intensity, stiffness, and disability of affected knee joints, and quality of life, as well as the adverse events.

Conclusion: The results of this study provide latest updated evidence of DHJSD monotherapy alone for KOA.

Ethics and dissemination: No ethical approval is required for this systematic review, because it is based on the published data, and not on individual patient data. Its findings is published in a peer-reviewed journal.

PROSPERO registration number: PROSPERO CRD42019120405.

Abbreviations: CENTRAL = Cochrane Central Register of Controlled Trials, DHJSD = Duohuojisheng decoction, KOA = knee osteoarthritis.

Keywords: Duohuojisheng decoction, efficacy, knee osteoarthritis, randomized controlled trial, safety

1. Introduction
Knee osteoarthritis (KOA) is a very common progressive joint disorder, especially in those aged 50 years and above.1–4 Patients with KOA often experience chronic pain, stiffness, swelling, movement restrictions of knee joint, poor quality of life, and psychiatric disorders.5–9 It has been reported that the prevalence of KOA ranges from 11.0% to 13.8% in Portuguese adults.10,11 In Chinese adult population, its overall prevalence rate is about 8.1%, with 17,128 Chinese residents aged 45 years and older.12 However, in the rural regions of China, the prevalence is about 16.57%, and the incidence is 29.25% for women and 24.71% for men aged 70 years and older.13

Treatments for this condition mainly focus on relieving knee pain, enhancing mobility and function, as well as improving the quality of life in patients with KOA.14,15 Traditional Chinese medicine (TCM), such as herbal medicine, acupuncture, moxibustion, Tai Chi, and so on, has been widely used to treat this condition in China.16–20 A variety of studies have reported to treat KOA by using Chinese herbal medicine, especially for the Duohuojisheng decoction (DHJSD).21,22 However, no systematic review has been conducted to assess the efficacy and safety of DHJSD monotherapy for the treatment of KOA. Therefore, this systematic review evaluates the efficacy and safety of DHJSD monotherapy for patients with KOA.

2. Methods
2.1. Eligibility criteria for study selection
2.1.1. Study types. All the randomized controlled trials (RCTs) of DHJSD monotherapy for KOA are included without language and publication type restriction. However, non-RCTs, cluster RCTs, and nonclinical trials are excluded.

2.1.2. Interventions. The therapeutic treatment applied in the experimental group is DHJSD monotherapy. Studies using DHJSD combination with any other interventions are not considered. The control group is any type of interventions, such as placebo, or medication therapy, except the DHJSD.
2.1.3. Participants. Trials involving participants with KOA are included without restrictions of age, sex, race, and education background.

2.1.4. Outcomes. The primary outcome is pain intensity, as measured by Visual Analog Scale, or Numeric Rating Scale, or any other relevant scales. The secondary outcomes are knee function and stiffness, as measured by Western Ontario and McMaster University Osteoarthritis Index or other scales, and quality of life, as measured by the 36-Item Short Form Survey or other instruments. Adverse events are also assessed.

2.2. Search methods for study inclusion

2.2.1. Electronic databases searches. Two researchers independently and electronically retrieved following databases of Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data from the inception to January 1, 2019. The detailed search strategy in CENTRAL database is shown in Table 1. Equivalent search strategy is built and applied to other electronic databases.

2.2.2. Searching other sources. Website of clinical trials registry and Google Scholar are searched. In addition, we manually searched the reference lists of included studies and relevant reviews to avoid missing any potential trials.

2.3. Data collection and analysis

2.3.1. Study selection. All potential literature were uploaded to the Endnote X7 system. Two researchers independently conducted the selection and recorded their decisions based on a standard eligibility form, and PRISMA flowchart. Any disagreements about the inclusion and exclusion of the studies were settled through the discussion by a third researcher. Procedure details this study selection are presented in Figure 1.

2.3.2. Data collection and missing data management. Two independent researchers read all included studies in full, collected the important information, and extracted the data via previous designed standardized data extraction form. The extracted information included general information (first author, published year, country, age, sex, funding, and setting), study methods (details of study design, sample size, randomization, concealment, blinding, insufficient reporting information, and any other potential risk of bias), interventions (period of treatment, follow-up, dosage, and types of treatments in both experimental and control groups), and outcomes (primary and secondary outcomes, and adverse events). The disagreements regarding the data extraction between the two researchers were judged by a third researcher through consultation.

If the data and essential information are insufficient or unclear, we will contact the authors from the primary trial to provide this information by email. If the missing data cannot be getable, then we will analyze the available data.

2.3.3. Assessment of risk of bias. The two researchers independently carried out the assessment of risk of bias by using the Cochrane Risk of Bias Tool. It consisted of seven domains, and each aspect was categorized into 3 levels: high, unclear, and low risk of bias. Any discrepancies were discussed by a third researcher involved.

2.3.4. Measurement of treatment effect. For continuous outcome data, a mean difference or standardized mean difference with 95% confidence intervals is applied to present the extracted data. For dichotomous outcome data, risk ratio with 95% confidence intervals is utilized to measure the treatment effect.

2.3.5. Unit of analysis. If the crossover studies are included in this systematic review, only the data of first phrase are used and analyzed. If included studies have multiple time point of outcome measurements, we combined the data into two term periods, including short term (within 5 weeks) and long term (over 5 weeks).

2.3.6. Heterogeneity evaluation. Heterogeneity is detected by the chi-squared test. If $I^2$ value is less than 50%, heterogeneity is considered as fair. Otherwise, it is considered as having significant heterogeneity among the included trials. Subgroup analysis is performed to explore the potentials factors of heterogeneity.

2.3.7. Subgroup analysis. Subgroup analysis is carried out for investigating the possible causes of substantial heterogeneity in accordance with the different locations, patient characteristics, interventions, controls, and outcomes measures.

2.3.8. Data synthesis. RevMan 5.3 software is employed for data synthesis and meta-analysis operation.

A fixed-effect model is applied to pool the data if $I^2$ value is less than 50%. Otherwise, a random-effect model is used for data synthesis. In such situation, subgroup analysis is also conducted. If the heterogeneity is still significant after the subgroup analysis, then the data are not considered to be pooled, and a narrative summary is described instead.

2.3.9. Sensitivity analysis. We carried out the sensitivity analysis to assess the robustness of studies based on the methodological quality, sample size, and missing data.

2.3.10. Reporting bias. Funnel plot is carried out if there are more than 10 trials included. Meanwhile, asymmetry on funnel plot is also checked by Egg’s regression and Begger’s tests.

3. Discussion

KOA is one of most common conditions of orthopedic diseases. If this condition can be treated fairly and effectively, it may greatly
affect the quality of life in patients with KOA. Numerous studies have reported that traditional Chinese can be utilized to treat this condition effectively, especially for the DHJSD monotherapy. However, no systematic review has addressed the efficacy and safety of DHJSD monotherapy for the treatment of KOA.

This systematic review firstly utilized rigorous methodology to assess studies reporting the outcomes of DHJSD monotherapy for KOA across all published RCTs. The findings of this study informed our understanding of the value of DHJSD monotherapy in treating KOA. This evidence may also be helpful to clinicians and patients.

**Acknowledgments**

This work was supported by the Heilongjiang Provincial Health and Family Planning Commission Research Project (NO.2017-400). The supporter was not allowed to join in any parts of this study.

**Author contributions**

Conceptualization: Zhi-ling Hou, Bo-yang Yuan, Qiang Bao.

Data curation: Zhi-ling Hou, Bo-yang Yuan, Ming-xia Fu, Lei Ni, Qiang Bao.

Formal analysis: Bo-yang Yuan.

Funding acquisition: Zhi-ling Hou.

Investigation: Ming-xia Fu.

Methodology: Zhi-ling Hou, Bo-yang Yuan, Ming-xia Fu, Lei Ni, Qiang Bao.

Project administration: Zhi-ling Hou, Qiang Bao.

Resources: Bo-yang Yuan, Ming-xia Fu, Qiang Bao.

Software: Zhi-ling Hou, Bo-yang Yuan, Lei Ni, Qiang Bao.

Supervision: Zhi-ling Hou, Lei Ni.

Validation: Zhi-ling Hou, Ming-xia Fu, Lei Ni.

Visualization: Zhi-ling Hou, Ming-xia Fu, Lei Ni.

Writing – original draft: Zhi-ling Hou, Bo-yang Yuan, Qiang Bao.

Writing – review & editing: Zhi-ling Hou, Bo-yang Yuan, Ming-xia Fu, Lei Ni, Qiang Bao.

**References**

[1] Mora JC, Przkora R, Cruz-Almeida Y. Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res 2018;11:2189–96.

[2] Rodriguez-Merchan EC. Topical therapies for knee osteoarthritis. Postgrad Med 2018;130:607–12.

[3] Xing D, Wang Q, Yang Z, et al. Evidence-based guidelines for intra-articular injection in knee osteoarthritis: Formulating and evaluating research questions. Int J Rheum Dis 2018;21:1533–42.
[4] Leighton R, Fitzpatrick J, Smith H, et al. Systematic clinical evidence review of NASHA (Durosolane hyaluronic acid) for the treatment of knee osteoarthritis. Open Access Rheumatol 2018;10:43–54.
[5] Dall’Oca C, Cengarle M, Costanzo A, et al. Current concepts in treatment of early knee osteoarthritis and osteochondral lesions; the role of biological augmentations. Acta Biomed 2017;88(4S):5–10.
[6] Chang J, Liao Z, Lu M, et al. Systemic and local adipose tissue in knee osteoarthritis. Osteoarthritis Cartilage 2018;26:864–71.
[7] Alman RD, Dasa V, Takeuchi J. Review of the mechanism of action for Supartz FX in knee osteoarthritis. Cartilage 2018;9:11–20.
[8] de Zwart AH, Dekker J, Lemm W, et al. Factors associated with upper leg muscle strength in knee osteoarthritis: a scoping review. J Rehabil Med 2018;50:140–50.
[9] Riccardo C, Fabio C, Pietro R. Knee osteoarthritis after reconstruction of isolated anterior cruciate ligament injuries: a systematic literature review. Joints 2017;5:39–43.
[10] Branco JC, Rodrigues AM, Gouveia N, et al. Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt – a national health survey. RMD Open 2016;2:e000166.
[11] Madaleno FO, Santos BA, Araújo VL, et al. Prevalence of knee osteoarthritis in former athletes: a systematic review with meta-analysis. Braz J Phys Ther 2018;22:437–51.
[12] Tang X, Wang S, Zhan S, et al. The prevalence of symptomatic knee osteoarthritis in China: results from the China Health and Retirement Longitudinal Study. Arthritis Rheumatol 2016;68:648–53.
[13] Liu Y, Zhang H, Liang N, et al. Prevalence and associated factors of knee osteoarthritis in a rural Chinese adult population: an epidemiological survey. J BMC Public Health 2016;16:94.
[14] Hussain SM, Neilly DW, Baliga S, et al. Knee osteoarthritis: a review of management options. Scott Med J 2016;61:7–16.
[15] Ondresik M, Azevedo Maia FR, da Silva Morais A, et al. Management of knee osteoarthritis. Current status and future trends. Biotechnol Bioeng 2017;114:717–39.
[16] Chen B, Zhan H, Marszalek J, et al. Traditional Chinese medications for knee osteoarthritis pain: a meta-analysis of randomized controlled trials. Am J Chin Med 2016;44:677–703.
[17] Yuan XC, Wang Q, Su W, et al. Electroacupuncture potentiates peripheral CB2 receptor-inhibited chronic pain in a mouse model of knee osteoarthritis. J Pain Res 2018;11:2797–808.
[18] Jun S, Lee JH, Gong HM, et al. Efficacy and safety of miniscalpel acupuncture on knee osteoarthritis: a randomized controlled pilot trial. J Pharmacopuncture 2018;21:151–8.
[19] Xu H, Zhao H, Kang L, et al. Moxibustion using different habitat moxa floss for moderate to severe primary knee osteoarthritis: study protocol for a three-armed randomized, double-blinded, sham-controlled trial. Trials 2018;19:403.
[20] Zhu L, Yang S, Wang S, et al. Effectiveness and safety of manufactured Chinese herbal formula for knee osteoarthritis: insights from a systematic review. Evid Based Complement Alternat Med 2015;2015:328642.
[21] Lian R, Fu YW. Clinical observation of treatment of knee arthritis with Duhuo Jisheng decoction. Bipedal Health Care 2018;27:168.
[22] Yang WH. A randomized controlled study of Duhuo Jisheng decoction in the treatment of knee arthritis. J Pract Inter Med 2017;31:7–9.